# A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma

> **NCT01634685** · PHASE1 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 15 (actual)

## Conditions studied

- Rectal Adenocarcinoma

## Interventions

- **RADIATION:** Radiation
- **DRUG:** Bavituximab
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT01634685
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-08
- **Primary completion:** 2015-10-30
- **Final completion:** 2017-10-06
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01634685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01634685, "A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01634685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*